The clinical outcome of oral squamous cell carcinoma (OSCC) has not improved in recent years, mainly due to the limited effective targeted therapy that has been applied. Recently, a transcriptional coactivator, YAP, has been shown to have a key regulatory role in malignant progression in multiple cancers, including OSCC. But pharmacologically targeting YAP or the Hippo pathway, which is the main signaling pathway regulating YAP, has been proven to be challenging. Therefore, uncovering YAP upstream regulators in cancer would identify novel therapeutic targets for treatment of YAP-sustained cancers. Here, we showed that YAP was overactivated in OSCC and that high YAP activity in patients with OSCC was associated with malignant progression and poor survival. We uncovered that GPR39 (a G protein–coupled receptor) was overexpressed in OSCC, that the expression level of GPR39 was correlated with the activity level of YAP, and that the high GPR39 expression was associated with malignant progression and poor survival in patients with OSCC. Moreover, we found that GPR39 regulated YAP through a Gαq/11-RhoA–dependent signaling pathway. Importantly, inhibition of GPR39 resulted in YAP-sustained OSCC growth inhibition. Our findings suggest that GPR39 is a potential therapeutic target for OSCC treatment with itself as a biomarker.
ArnoldJJBlinderKJBresslerNMBresslerSBBurdanAHaynesLLimJIMillerJWPotterMJReavesA, et al. 2004. Acute severe visual acuity decrease after photodynamic therapy with verteporfin: case reports from randomized clinical trials-TAP and VIP report no. 3. Am J Ophthalmol. 137(4):683–696.
2.
AsrafHSalomonSNevoASeklerIMayerDHershfinkelM.2014. The ZnR/GPR39 interacts with the CaSR to enhance signaling in prostate and salivary epithelia. J Cell Physiol. 229(7):868–877.
3.
AzabMBenchabouneMBlinderKJBresslerNMBresslerSBGragoudasESFishGEHaoYHaynesLLimJI, et al. 2004. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: meta-analysis of 2-year safety results in three randomized clinical trials: Treatment of Age-Related Macular Degeneration with Photodynamic Therapy and Verteporfin in Photodynamic Therapy Study Report no. 4. Retina. 24(1):1–12.
4.
BarbazettoIBurdanABresslerNMBresslerSBHaynesLKapetaniosADLukasJOlsenKPotterMReavesA, et al. 2003. Photodynamic therapy of subfoveal choroidal neovascularization with verteporfin: fluorescein angiographic guidelines for evaluation and treatment—TAP and VIP report no. 2. Arch Ophthalmol. 121(9):1253–1268.
5.
BrayFFerlayJSoerjomataramISiegelRLTorreLAJemalA.2018. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 68(6):394–424.
6.
ChenQDanHTangFWangJLiXChengJZhaoHZengX.2019. Photodynamic therapy guidelines for the management of oral leucoplakia. Int J Oral Sci. 11(2):14.
7.
ChenXGuWWangQFuXWangYXuXWenY.2018. C-MYC and BCL-2 mediate YAP-regulated tumorigenesis in OSCC. Oncotarget. 9(1):668–679.
8.
DolginE. 2018. First GPCR-directed antibody passes approval milestone. Nat Rev Drug Discov. 17(7):457–459.
9.
DorsamRTGutkindJS. 2007. G-protein-coupled receptors and cancer. Nat Rev Cancer. 7(2):79–94.
10.
DuYPeyserNDGrandisJR. 2014. Integration of molecular targeted therapy with radiation in head and neck cancer. Pharmacol Ther. 142(1):88–98.
11.
DubiNGheberLFishmanDSeklerIHershfinkelM.2008. Extracellular zinc and zinc-citrate, acting through a putative zinc-sensing receptor, regulate growth and survival of prostate cancer cells. Carcinogenesis. 29(9):1692–1700.
12.
FengXArangNRigiraccioloDCLeeJSYeernaHWangZLubranoSKishoreAPachterJAKönigGM, et al. 2019. A platform of synthetic lethal gene interaction networks reveals that the GNAQ uveal melanoma oncogene controls the Hippo pathway through FAK. Cancer Cell. 35(3):457–472.e5.
13.
FengXDegeseMSIglesias-BartolomeRVaqueJPMolinoloAARodriguesMZaidiMRKsanderBRMerlinoGSodhiA, et al. 2014. Hippo-independent activation of YAP by the GNAQ uveal melanoma oncogene through a trio-regulated rho GTPase signaling circuitry. Cancer Cell. 25(6):831–845.
14.
FerrisRLBlumenscheinGJrFayetteJGuigayJColevasADLicitraLHarringtonKKasperSVokesEEEvenC, et al. 2016. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med. 375(19):1856–1867.
15.
FlemingJKWojciakJMCampbellMAHuxfordT.2011. Biochemical and structural characterization of lysophosphatidic acid binding by a humanized monoclonal antibody. J Mol Biol. 408(3):462–476.
16.
FunkGFKarnellLHRobinsonRAZhenWKTraskDKHoffmanHT. 2002. Presentation, treatment, and outcome of oral cavity cancer: a National Cancer Data Base report. Head Neck. 24(2):165–180.
17.
HauserASAttwoodMMRask-AndersenMSchiöthHBGloriamDE. 2017. Trends in GPCR drug discovery: new agents, targets and indications. Nat Rev Drug Discov. 16(12):829–842.
18.
HershfinkelM. 2018. The zinc sensing receptor, ZnR/GPR39, in health and disease. Int J Mol Sci. 19(2):E439.
19.
HiemerSEZhangLKarthaVKPackerTSAlmershedMNoonanVKukuruzinskaMBaisMVMontiSVarelasX.2015. A YAP/TAZ-regulated molecular signature is associated with oral squamous cell carcinoma. Mol Cancer Res. 13(6):957–968.
20.
MartinDDegeseMSVitale-CrossLIglesias-BartolomeRValeraJWangZFengXYeernaHVadmalVMoroishiT, et al. 2018. Assembly and activation of the Hippo signalome by FAT1 tumor suppressor. Nat Commun. 9(1):2372.
21.
MoecharsDDepoortereIMoreauxBde SmetBGorisIHoskensLDaneelsGKassSVer DonckLPeetersT, et al. 2006. Altered gastrointestinal and metabolic function in the GPR39-obestatin receptor-knockout mouse. Gastroenterology. 131(4):1131–1141.
22.
O’CallaghanKKuliopulosACovicL.2012. Turning receptors on and off with intracellular pepducins: new insights into G-protein-coupled receptor drug development. J Biol Chem. 287(16):12787–12796.
23.
PanD. 2010. The Hippo signaling pathway in development and cancer. Dev Cell. 19(4):491–505.
24.
PengCHLiaoCTPengSCChenYJChengAJJuangJLTsaiCYChenTCChuangYJTangCY, et al. 2011. A novel molecular signature identified by systems genetics approach predicts prognosis in oral squamous cell carcinoma. PLoS One. 6(8):e23452.
25.
PonnusamySSelvamSPMehrotraSKawamoriTSniderAJObeidLMShaoYSabbadiniROgretmenB.2012. Communication between host organism and cancer cells is transduced by systemic sphingosine kinase 1/sphingosine 1-phosphate signalling to regulate tumour metastasis. EMBO Mol Med. 4(8):761–775.
26.
PyeonDNewtonMALambertPFden BoonJASenguptaSMarsitCJWoodworthCDConnorJPHaugenTHSmithEM, et al. 2007. Fundamental differences in cell cycle deregulation in human papillomavirus-positive and human papillomavirus-negative head/neck and cervical cancers. Cancer Res. 67(10):4605–4619.
27.
Sanchez-VegaFMinaMArmeniaJChatilaWKLunaALaKCDimitriadoySLiuDLKanthetiHSSaghafiniaS, et al. 2018. Oncogenic signaling pathways in The Cancer Genome Atlas. Cell. 173(2):321–337.e10.
28.
SoucekPCihelkovaI.2006. Photodynamic therapy with verteporfin in subfoveal amelanotic choroidal melanoma (a controlled case). Neuro Endocrinol Lett. 27(1–2):145–148.
29.
SriramKInselPA. 2018. G protein–coupled receptors as targets for approved drugs: how many targets and how many drugs. Mol Pharmacol. 93(4):251–258.
30.
SunuwarLGiladDHershfinkelM.2017. The zinc sensing receptor, ZnR/GPR39, in health and disease. Front Biosci (Landmark Ed). 22:1469–1492.
31.
TanFZhuHTaoYYuNPeiQLiuHZhouYXuHSongXLiY, et al. 2015. Neuron navigator 2 overexpression indicates poor prognosis of colorectal cancer and promotes invasion through the SSH1L/cofilin-1 pathway. J Exp Clin Cancer Res. 34:117.
32.
VarelasXKukuruzinskaMA. 2014. Head and neck cancer: from research to therapy and cure. Ann N Y Acad Sci. 1333:1–32.
33.
WuVYeernaHNohataNChiouJHarismendyORaimondiFInoueARussellRBTamayoPGutkindJS. 2019. Illuminating the Onco-GPCRome: novel G protein–coupled receptor-driven oncocrine networks and targets for cancer immunotherapy. J Biol Chem. 294(29):11062–11086.
34.
XieFLiuHZhuYHQinYRDaiYZengTChenLNieCTangHLiY, et al. 2011. Overexpression of GPR39 contributes to malignant development of human esophageal squamous cell carcinoma. BMC Cancer. 11:86.
YuFXGuanKL. 2013. The Hippo pathway: regulators and regulations. Genes Dev. 27(4):355–371.
37.
YuFXLuoJMoJSLiuGKimYCMengZZhaoLPeymanGOuyangHJiangW, et al. 2014. Mutant Gq/11 promote uveal melanoma tumorigenesis by activating YAP. Cancer Cell. 25(6):822–830.
38.
YuFXZhaoBGuanKL. 2015. Hippo pathway in organ size control, tissue homeostasis, and cancer. Cell. 163(4):811–828.
39.
YuFXZhaoBPanupinthuNJewellJLLianIWangLHZhaoJYuanHTumanengKLiH, et al. 2012. Regulation of the Hippo-YAP pathway by G-protein-coupled receptor signaling. Cell. 150(4):780–791.
40.
ZanconatoFCordenonsiMPiccoloS.2016. YAP/TAZ at the roots of cancer. Cancer Cell. 29(6):783–803.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
